Question.2747 - This assignment focuses on treatment for schizophrenia, and it assesses ULO 4.4. Instructions Review the DSM-5 criteria for schizophrenia (a good resource is this Cleveland Clinic web page (https://my.clevelandclinic.org/health/diseases/4568-schizophrenia) ). Then, complete the following: Identify and describe two pharmaceutical and three alternative treatments for schizophrenia. Describe each treatment and what is known about the effectiveness and access (such as cost, time commitment, side effects, etc.). Formatting Expectations Use APA guidelines for this assignment (12-point font, 1-inch margins, double spaced). A good resource is OWL (https://owl.purdue.edu/index.html) or Averett’s Writing Center. The content, or body, of your paper should be two pages. All sources should be referenced. Additional resources may include your textbook, other readings or videos, and study materials.
Answer Below:
IntroductionSchizophrenia xx a xxxxxx disorder xxxxx disrupts xxx functioning xx the xxxxx The xxxxxx has xxxxxxxxxxx the xxxxxxxxxx used xx the xxxxxxx to xxxx the xxxxxxxx suffering xxxx the xxxxxxxx It xxx also xxxxxxxxx the xxxxxxxxxxxxxx and xxxxxxxxxxx treatments xx help xxx people xxx are xxxxxxxx nbsp xxxxxxxxxx Two xxxxxxxxxxxxxx and xxxxx alternative xxxxxxxxxx for xxxxxxxxxxxxx Schizophrenia xx a xxxxxx treatable xxxxxxxx and x small xxxxxx of xxxxxx have xxxxxxxxx from xx as xxxx The xxxxxxxxxxxxxx treatments xxx schizophrenia xxx as xxxxxxx Antipsychotic xxxxxxxxxxxxxxxxxxxxxxxx drugs xxx used xx treat xxxxxxxxxxxxx which xx a xxxxxxxxx related xx psychosis xxx example x person xxxxxxxxx from xxxxxxxx and xxxxxxxxxxxxxx causes x severe xxxxxxxxxxxxxx from xxxxxxx Antipsychosis xxxxxxxxx blocks xxx receptors xxxxx include xxx -HT x nbsp xxxx and x for xxxxxxxxxx dopaminergic xxxxxxxxxxxxxxxxx reduction xxxx examples xx antipsychosis xxxxx are xxxxxxxxxxxxxx Thorazine xxxxxxxxxxxx Prolixin xxxxxxxxxxx Haldol xxxxxxxxxxxx Trilafon xxxxxxxxxxxx Mellaril xxx Effectiveness xxx access xx Antipsychotic xxxxxxxxxxx The xxxxx help xxx patients xxxx acute xxxxxxxxx to xxxxx the xxxxxxxxx and xxxx the xxxx within xxxx to xxx weeks xxxx the xxxx of xxxxxxxxxxx patients xxxxxxx the xxxxxxxx however xxxxx medications xx not xxxx nbsp xxx anti-psychosis xxxxxxxxxxx are xxxxxxxxxx on x long-term xxxxx for xxx prevention xx relapses xxx amelioration xx the xxxxxxx symptoms xxxxxxxxxxxxx drugs xxx costly xxxxxxx of xxx brand xxxx that xx involved xx it xxxxx in xxxxxxxxxx the xxxxxxxx of xxxxxxx for xxx research xx make xx effective xxx safe xxxx of xxx side xxxxxxx of xxx antipsychotic xxxxx are xxxxxxx vision xxx dry xxxxx mdash xxxxx retention xxx nbsp xxxxxxxxxxxxxx MedicationsThe xxxxxxxxxxx for xxxxxxxxxxxxxxx can xx used xxx the xxxxxxxxx of xxxxxxxxxxxxx in xxxxxxxx In xxxxxx clinical xxxxxxxx the xxxxxxxxx treatment xxx schizophrenia xx monopharmacy xxxx antidepressants xxx antipsychotics xxxxxxxxx et xx Moreover xxxxxxxxxxxxxxx block xxx monoamine xxxxxxxx and xxx to xxxxxxxx monoaminergic xxxxxxxxxxxxxxxxx which xxx help xxxxxxxx with xxxxxxxx of xxxxxxxxxx in xxxxxxxxxxxxx Some xx the xxxxxxxx of xxxxxxxxxxxxxxx used xxx schizophrenic xxxxxxxx are xxxxxxxxxx Celexa xxxxxxxxxx Prozac xxxxxxxxxx Paxil xxxxxx Sertraline xxxxxx Escitalopram xxxxxxx etc xxxxxxxxxxxxx and xxxxxx to xxxxxxxxxxxxxx MedicationsAntidepressants xxxxxx in xxx they xxxx the xxxx of xxxxxxxxxxx used xxxxxxxx and xxxx These xxxxxxx mainly xxxxxxxxx the xxxx of xxxx drug xxxxxxx the xxxxxxx medication xxxxx about xxxx - xxx month xxxx For x significant xxxxxxxx antidepressants xxxxx take xxx or xxxx weeks xxx there xx much xxxxxx process xx the xxxxxx of xxx antidepressant xxx to xx titrated xxxxx et xx Some xx the xxxxxxxxxxxxxxx are xxxxxxxxxxxxxx confusion xxxxxxxxxx in xxxxxxxxx etc xxxxxxxxxxx treatment xxx schizophreniaCognitive xxxxxxxxxx therapy xxxx is xxx of xxx most xxxxxxxxxx talk xxxxxxx which xxx help xxxxxxxx suffering xxxx schizophrenia xx manage xxxxx symptoms xxxxxx Cognitive xxxxxxxxxx therapy xxx a xxxxxx effect xx severe xxxxx of xxxxxxx complaints xxxx auditory xxxxxxxxxxxxxx and xxxxxxxx related xx delusions xxxxxx et xx Effectiveness xxx access xx Cognitive xxxxxxxxxx therapyTherapy xx an xxxxxxxxx process xx it xxxxxx the xxxx spent xxxx the xxxxxxxxx while xxxxxxxxx the xxxxxxx Talk xxxxxxx helps xxxxxxx the xxxxxxx of xxxx and xxxxx patients xxxxxxx specific xxxxxxxx An xxxxxxx therapy xxxxx between xxxxx With xxxxxxxxx it xxx be xxxxxxx Therapy xxxxx longer xx it xx done xx an xxxxxxxxxx basis xxx will xxxx and xxxxxxxxxxx or xxxxxx sessions xxxxx will xxxx to xxxxxxx Therapy xx an xxxxxxxxx method xxx patients xxxx schizophrenia xxxxxxx for xxxxxxxx with xxxxxxx mental xxxxxx issues xxxxxxxxx might xx a xxxxxxxxx Electroconvulsive xxxxxxx is xxxx for xxx patients xx schizophrenia xxxxx a xxxx electrical xxxxxxx to xxxxx a xxxxxxx It xxxxx in xxxxxxxxxx discomfort xx using xxx electrical xxxxxxxxx safely xxx primary xxxx of xxxxxxxxxxxxxxxxx therapy xxx schizophrenic xxxxxxxx is xx focus xx the xxxxxxx of xxxxxxxxx functions xxx efficacy xxx role xx neuroimaging xxxxxxxxxx and xxx role xx ECT xxxxxxxxxxx Ali xx al xxxxxxxxxxxxx and xxxxxx to xxxxxxxxxxxxxxxxx therapy xx the xx the xxx cost xxxxxx from xx making xx costly xxxx annual xxxxxxx of xx more xxxx of xxx serious xxxx effects xx ECT xxx confusion xxxxxxxx slight xxxxxx loss xxx fatigue xxxxx symptoms xxx last xxx several xxxxx and xxxxx are xxxxxxx risks xxxxxxxx with xxx effectively xxxxxxx disorders xxxxxxxxx enhancement xxxxxxx CET xxxx is xxxx for xxxxxxxx to xxxxxxxxx triggers xx social xxxx and xxxxxxx their xxxxxx ability xx organize xxxxx thoughts xxx memory xxx CET xxxxxxx is xxxxxxxxxx as xx trains xxx patients xxxx the xxxx of xxxxx sessions xxx brain xxxxxxxx Effectiveness xxx access xx CETA xxxxxxxx -month xxxxxxxxx remediation xxxxxxxxxxxx is xxxxxxxx for xxxxxxxxx enhancement xxxxxxx to xxxxxxx the xxxxxxxxxxx and xxxxxxxxx of xxxxxxxxxxxxx disorder xxx cost xx CET xx dependent xx the xxxxxxxx duration xxx expertise xx the xxxxxxx provider xxxxxxxx enhancement xxxxxxx is xxxx to xxxxxxx cognitive xxxxxxxxx however xxxx of xxx side xxxxxxx of xxx therapy xxxxxxx changes xx mood xxxxxxx and xxxxxxxxx alertness xxxxxxxxxx There xxx different xxxxxxx to xxxxx the xxxxx art xxxxxxxxx of xxxxxxxxxxxxx these xxxxxxx help xxx patients xxxx the xxxxxxxx to xxxxxxx their xxxxxxxxx functioning xx can xx concluded xxxx the xxxxxx that xxxxx are xxxxxxxxx ways xx treating xxxxxxxxxxxxx which xxxxxxx antipsychotic xxxxx and xxxxxxxxxxxxxxx with xxx help xx cognitive xxxxxxxxxx therapy xxxxxxxxx enhancement xxxxxxx CET xxx Electroconvulsive xxxxxxx These xxxxxxxxxx help xxx patients xxxxxxx their xxxxx ReferencesAli x A xxxxxx N xxxxxxxx A x amp xxxxx R x Electroconvulsive xxxxxxx and xxxxxxxxxxxxx a xxxxxxxxxx review xxxxxxx Psychiatry x Hashimoto x Yasui-Furukori x Hasegawa x Ishikawa x Numata x Hori x amp xxxxxxxxx R xxxxxxxxxxxxxxx of xxxxxxxxx prescriptions xxx patients xxxx schizophrenia xx major xxxxxxxxxx disorder xxxxxxxxxx evidence xxxx the xxxxxxxxxxxxx of xxxxxxxxxx for xxxxxxxxxxxxx and xxxxxxxxx EGUIDE xxxxxxxxxxx treatment xxxxxxx Asian xxxxxxx of xxxxxxxxxx Jauhar x Laws x R xxx McKenna x J xxx for xxxxxxxxxxxxx a xxxxxxxx viewpoint xxxxxxxxxxxxx medicine x Malhi x S xxxx E xxxxxx G xxx Hamilton x The xxxxx in xxxxxxxx to xxxxxxxxxxxxxx therapy x window xx opportunity xxxxxxxxxx amp xxx Zealand xxxxxxx of xxxxxxxxxx -More Articles From Psychology
.ico)
.ico)
.ico)
.ico)
